Table of Contents

|                                                                |
|----------------------------------------------------------------|
|                                                                |  |
| Delaware                                                       | 63-0860407 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

|                                              |
|----------------------------------------------|
|                                              |
| Stephen D. Leasure, Esq.                     |
| Vice President and Associate General Counsel |
| HealthSouth Corporation                      |
| 3660 Grandview Parkway, Suite 200            |
| Birmingham, Alabama 35243                    |
| (205) 967-7116                               |

|                                               |
|-----------------------------------------------|
|                                               |  |  |  |  |
| Large accelerated filer                       | ý |   | Accelerated filer  | ¨ |
| Non-Accelerated filer                         | ¨ |   | Smaller reporting company | ¨ |
| (Do not check if a smaller reporting company) |

|                                                                                         |
|-----------------------------------------------------------------------------------------|
|                                                                                         |  |  |  |  |
| Title of Each Class ofSecurities to be Registered                                       | Amount to beRegistered(1) | ProposedMaximum Offering Price Per Security | Proposed MaximumAggregateOffering Price | Amount ofRegistration Fee |
| Common Stock Warrants(2)                                                                | 5,408,528 | — | — | — |
| Common Stock, par value $.01 per share, issuable upon exercise of Common Stock Warrants | 1,119,586 | $34.20(3) | $38,289,841.20(3) | $4,931.73 |

----

Table of Contents

----

----

Table of Contents

----

Table of Contents

|                                                   |
|---------------------------------------------------|
|                                                   |  |
|                                              | Page |
| About the Prospectus                              | ii |
| Forward-Looking Statements                        | iii |
| Prospectus Summary                                | 1 |
| Risk Factors                                      | 3 |
| Use of Proceeds                                   | 6 |
| Selling Securityholders                           | 7 |
| Description of Common Stock                       | 9 |
| Description of Warrants                           | 10 |
| Certain U.S. Federal Income Tax Considerations    | 14 |
| Plan of Distribution                              | 18 |
| Where You Can Find More Information               | 19 |
| Incorporation of Certain Information By Reference | 20 |
| Legal Matters                                     | 21 |
| Experts                                           | 22 |

----

Table of Contents

----

Table of Contents

|         |                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | each of the factors discussed in Item 1A, Risk Factors, of our Annual Report on Form 10-K for the year ended December 31, 2012, as may be updated or supplemented in our other SEC filings that are incorporated herein and into any prospectus supplement by reference; |

|         |                                                                                                                                                                                      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | uncertainties and factors discussed elsewhere in our current and periodic filings we make with the SEC that are incorporated herein and into any prospectus supplement by reference; |

|         |                                                                                                                                                                                                                                                                                             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | changes in the regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction, and related increases in the costs of complying with such changes; |

|         |                                                                                                                                                                                                         |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our ability to obtain and retain favorable arrangements with third-party payors; |

|         |                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | increased costs of regulatory compliance and compliance monitoring in the healthcare industry, including the costs of investigating and defending asserted claims, whether meritorious or not; |

|         |                                                                                                                                                                                                                                                                             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to attract and retain nurses, therapists and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on our labor expenses from potential union activity and staffing recruitment and retention; |

|         |                                                                                       |
|---------|---------------------------------------------------------------------------------------|
| • | competitive pressures in the healthcare industry and our response to those pressures; |

|         |                                                                                                                                                                                                                                                                                               |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to successfully complete and integrate de novo developments, acquisitions, investments and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings and productivity improvements arising from the related operations; |

|         |                                                                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | any adverse outcome of various lawsuits, claims and legal or regulatory proceedings involving us, including the ongoing investigations by the U.S. Department of Health and Human Services, Office of the Inspector General; |

|         |                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | increased costs of defending and insuring against alleged professional liability and other claims and the ability to predict the costs related to such claims; |

|         |                                                                                                                         |
|---------|-------------------------------------------------------------------------------------------------------------------------|
| • | potential disruptions or incidents affecting the proper operation, availability or security of our information systems; |

|         |                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the price of our common or preferred stock as it affects our willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; |

|         |                                                                                           |
|---------|-------------------------------------------------------------------------------------------|
| • | our ability and willingness to continue to declare and pay dividends on our common stock; |

|         |                                                                 |
|---------|-----------------------------------------------------------------|
| • | our ability to attract and retain key management personnel; and |

|         |                                                        |
|---------|--------------------------------------------------------|
| • | general conditions in the economy and capital markets. |

----

Table of Contents

|                                               |
|-----------------------------------------------|
|                                               |  |
| Issuer                                        | HealthSouth Corporation. |
| Securities Offered by Selling Securityholders | Up to 5,408,528 Warrants, each entitling the holder thereof to purchase one-fifth of a share of our common stock. |
| Exercise Period                               | Each Warrant is exercisable at any time on or prior to January 16, 2014. |
| Exercise Price                                | Each Warrant entitles its holder to purchase one-fifth of a share of our common stock at an exercise price of $6.50, representing a per share equivalent of $32.50 per share. The per share exercise price reflects our one-for-five reverse stock split in October 2006. See “Description of Warrants-Exercise of Warrants.” |
| No Fractional Shares                          | We will not issue fractional shares of our common stock upon the exercise of the Warrants. If you exercise a number of Warrants that is not a multiple of five, you will receive cash in lieu of fractional shares based on the market price of our common stock as provided herein. See “Description of Warrants-Exercise of Warrants.” |
| Repurchase Offers                             | We will offer to repurchase all outstanding Warrants, subject to certain limitations, in the event of certain business combination transactions pursuant to which the common stock thereafter issuable upon exercise of the Warrants is not registered. See “Description of Warrants-Repurchase Offers.” |

----

Table of Contents

|                                  |
|----------------------------------|
|                                  |  |
| Adjustments                      | The exercise price of each Warrant and the number of shares of common stock purchasable upon the exercise of each Warrant may be adjusted, subject to certain exceptions, upon (a) payment of a dividend or distribution, (b) subdivision of the common stock, (c) consolidation of the common stock, (d) reclassification or conversion of common stock, (e) merger or other business combination transactions, (f) issuance of rights or privileges to purchase common stock at a price that is lower than the current value of the stock, and (g) distributions of debt, assets, subscription rights or convertible securities.On July 25, 2013, our board of directors approved the initiation of a quarterly cash dividend on our common stock of $0.18 per share. The first quarterly dividend has been declared and was paid on October 15, 2013 to stockholders of record as of the close of business on October 1, 2013. On October 25, 2013, our board declared another quarterly cash dividend on our common stock of $0.18 per share, payable on January 15, 2014 to stockholders of record as of the close of business on January 2, 2014. The Company expects quarterly dividends to be paid in January, April, July and October. However, the actual declaration and amount of any future cash dividends, and the establishment of record and payment dates, will be subject to final approval by our board each quarter after consideration of various factors, including our capital position and the best interests of our stockholders.As noted above, the Warrants provide that the shares issuable upon exercise and the exercise price will be adjusted for common stock dividends after a de minimis threshold. Based upon the declaration of the $0.18 per share dividend payable on January 15, 2014, we expect the de minimis threshold will be exceeded and the exercise price of the Warrants will adjust. See “Description of Warrants-Adjustments.” |
| Warrant Holder not a Stockholder | Prior to their exercise, the Warrants do not entitle the holders to any voting or other rights as are accorded to our stockholders. |
| Tax Consequences                 | For a discussion of certain U.S. federal income tax consequences with respect to the ownership, exercise and disposition of the Warrants, see “Certain U.S. Federal Income Tax Considerations.” |
| Registration Rights              | We agreed to file a registration statement with respect to the Warrants and the shares of common stock issuable upon exercise thereof. Pursuant to the Registration Rights Agreement, we are required to file a registration statement with the SEC in a timely manner. We filed the registration statement of which this prospectus forms a part with the SEC pursuant to the registration rights granted in connection with the original issuance of the Warrants. We will use our reasonable best efforts to keep this registration statement continually effective for the requisite period, but will be permitted to suspend the use of this prospectus for a period not to exceed sixty (60) consecutive days under certain circumstances. See “Description of Warrants-Registration Rights.” |
| Risk Factors                     | See “Risk Factors” beginning on page 3 of this prospectus and the risk factors discussed in any prospectus supplement and in our current and future SEC filings that are incorporated by reference herein and therein for a discussion of the factors you should carefully consider before deciding to invest in the Warrants. |
| Recent Developments              | On November 12, 2013, we entered into separate, privately negotiated exchange agreements under which we agreed to exchange 257,110 shares of our outstanding 6.50% Series A Convertible Perpetual Preferred Stock, par value $0.10 per share and liquidation preference $1,000 per share, for $320 million in aggregate principal amount of newly issued 2.00% Convertible Senior Subordinated Notes due 2043. On November 18, 2013, we closed these exchange transactions and entered into an indenture with Wells Fargo Bank, National Association, as trustee, paying agent, conversion agent, and registrar, pursuant to which these convertible notes were issued. Following the closing of the exchange transactions, 96,245 shares of the preferred stock remain outstanding. The exchange transactions are expected to result in a $0.63 per basic share net reduction to earnings per share for 2013. This net reduction is expected to result from the approximate $74 million, or $0.84 per basic share, repurchase premium and fees on the preferred stock in the exchange transactions, a decrease in preferred dividends accrued in the fourth quarter of 2013, an increase in interest expense resulting from the exchange transactions, plus the impact of calculating earnings per share on a basic versus a diluted basis. |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|         |                                          |
|---------|------------------------------------------|
| • | the name of each selling securityholder; |

|         |                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the number of Warrants and the number of shares of our common stock issuable upon exercise that may be sold by the selling securityholders; and |

|         |                                                                                                                                         |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------|
| • | the number and percent of shares of common stock to be beneficially owned by each selling securityholder before and after the offering. |

|                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                |  |  |  |  |  |  |  |
| Name                                                                                                                           | Number of Warrants Beneficially Owned Prior to Offering | Number of Warrants that May be Offered Hereby (1) | Percentage of Outstanding Warrants | Shares of Common Stock Beneficially Owned Prior to Offering | Shares of Common Stock Beneficially Owned After Offering |
| Number (2)(3)                                                                                                                  | Percent (4) | Number | Percent (4) |
| CC Arbitrage, Ltd.(5)                                                                                                          | — | — | * | 11,856 | * | — | — |
| CC ARB SIF I, Ltd.(5)                                                                                                          | — | — | * | 13,259 | * | — | — |
| CC ARB West, LLC(5)                                                                                                            | — | — | * | 12,766 | * | — | — |
| All other holders of the Warrants (and future transferees, distributees, pledgees, donees or successors of such holders)(6)(7) | 5,408,528 | 5,408,528 | 100% | 1,081,705 | 1.2% | — | — |
| *Less than 1%                                                                                                                  |   |   |   |   |   |   |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Assumes exercise for cash of the entire amount of Warrants held by the selling securityholders at a rate of one-fifth of a share of our common stock per Warrant. The number of shares of our common stock issuable upon exercise of the Warrants may be adjusted under circumstances described under “Description of Warrants-Adjustments.” Under the terms of the Warrants, cash will be paid instead of issuing any fractional shares. |

|     |                                                                                                                                                                                                         |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Includes that number of shares of our common stock underlying the Warrants beneficially owned by each selling securityholder. Each Warrant is exercisable for one-fifth of a share of our common stock. |

----

Table of Contents

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Includes that number of shares underlying our Series A Preferred Stock owned by each selling securityholder that are convertible at the option of such holder into shares of our common stock pursuant to the terms of the Certificate of Designations establishing such series of preferred stock. Assumes all shares of the Series A Preferred Stock are converted into shares of our common stock. Pursuant to the Certificate of Designation establishing the Series A Preferred Stock, we may elect to satisfy the conversion obligation with cash or a combination of cash and shares of our common stock. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | This percentage is calculated using as the numerator the number of shares of common stock included in the previous column and as the denominator 87,429,848 shares of common stock issued and outstanding, net of treasury shares, on October 23, 2013, plus the shares of common stock underlying the Warrants and the preferred stock beneficially owned by each such individual stockholders and deemed to be outstanding pursuant to Rule 13d-3(d)(1) under the Exchange Act. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | Castle Creek Arbitrage LLC (the “Advisor”), is the investment manager of CC ARB West, LLC, CC ARB SIF I, Ltd. and CC Arbitrage, Ltd.  (each, a “Fund”) and sole voting and dispositive power over the securities held by each Fund. Mr. Allan Weine, the managing member of the Advisor, has the authority to direct the voting and disposition of securities held by the Fund. The Advisor and Mr. Weine each disclaim beneficial ownership over securities held by each Fund, except to the extent of any indirect ownership interest resulting from an economic participation in such Fund. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | Information concerning other selling securityholders will be set forth in prospectus supplements or in an amendment to the registration statement of which this prospectus is a part if and when necessary. Totals in these columns may exceed the number of Warrants and common stock offered by this prospectus as a result of the selling securityholders identified above having sold, transferred or otherwise disposed of some or all of their Warrants since the date on which the information in the preceding table was provided to us without informing us of such sale(s). In no event will the number of Warrants offered by this prospectus or any related prospectus supplement exceed 5,408,528. Similarly, the total number of shares of our common stock issuable upon the exercise of all the Warrants may increase or decrease due to adjustments to the exercise price resulting from certain transactions by the company such as payment of dividends on its common stock. Pursuant to Rule 416 under the Securities Act, the registration statement of which this prospectus is a part also covers any additional shares of our common stock which become issuable in connection with the Warrants because of any dividend, stock split, recapitalization or other similar event or adjustment in the number of shares issuable upon exercise of the Warrants. |

|     |                                                                                                                                                                                                                                                                                            |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (7) | Assumes all other holders of the outstanding Warrants (and future transferees, distributees, pledgees, donees or successors of such holders) do not beneficially own shares of our common stock, other than those shares of our common stock underlying the Warrants held by such holders. |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | in the event we, on or before January 16, 2014, (a) issue any shares of our common stock in payment of a dividend or distribution with respect to our common stock or other shares of capital stock, (b) subdivide our issued and outstanding shares of common stock, (c) consolidate our issued and outstanding shares of common stock into a smaller number of shares or (d) reclassify or convert the shares of our common stock (other than a reclassification in connection with a business combination transaction); |

|         |                                                                                                                                                                                                                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | in the event we issue any rights, options, Warrants or convertible or exchangeable securities (other than as described above) to all holders of shares of our common stock, entitling them to subscribe for or purchase shares of common stock at a price per share which is lower than the then-current market value per share; |

|         |                                                                                                                                                                                                                   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | in the event we decrease the purchase price per share of any outstanding rights, options, Warrants or convertible or exchangeable securities (other than under a provision designed to protect against dilution); |

|         |                                                                                                                                                                                                                                                                                                          |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | in the event we increase the number of shares of common stock which may be purchased or subscribed for upon exercise, exchange or conversion of any outstanding rights, options, Warrants or convertible or exchangeable securities (other than under a provision designed to protect against dilution); |

|         |                                                                                                                                                                                                                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | in the event we sell and issue any shares of our common stock or rights related thereto (other than as described above or in connection with a merger or certain other business combination transactions) at a price per share that is lower than the current market value per share in effect immediately prior to the date of such sale or issuance; |

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | in the event we make a distribution to holders of shares of our common stock of (a) evidences of our indebtedness, or assets, or other dividends or distributions, or (b) any options, Warrants or other rights to subscribe for or purchase any of the foregoing (other than (i) any issuance of common shares pursuant to adjustment for payment of a dividend, subdivision, consolidation or reclassification, (ii) distributions in connection with the dissolution, liquidation or winding-up of the Company and (iii) distributions of securities as described above); and |

|         |                                                                                                                                                                                                                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | upon the expiration of any rights, options, Warrants or conversion or exchange privileges that have previously resulted in an adjustment, if any thereof shall not have been exercised, exchanged or converted. |

----

Table of Contents

|         |                                                            |
|---------|------------------------------------------------------------|
| • | resale of the Warrants by the selling securityholders; and |

|         |                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------|
| • | resales of the shares of common stock issuable upon exercise of the Warrants by the selling securityholders. |

----

Table of Contents

|         |                                                          |
|---------|----------------------------------------------------------|
| • | the date on which the Warrants expire, January 16, 2014; |

|         |                                                                                             |
|---------|---------------------------------------------------------------------------------------------|
| • | the date on which the Warrants have been exercised pursuant to a registration statement; or |

|         |                                                                                                                                                                   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the date on which the underlying common stock has been disposed of in accordance with a registration statement or distributed to the public pursuant to Rule 144. |

----

Table of Contents

|         |                                 |
|---------|---------------------------------|
| • | certain financial institutions; |

|         |                      |
|---------|----------------------|
| • | insurance companies; |

|         |                                              |
|---------|----------------------------------------------|
| • | dealers in securities or foreign currencies; |

|         |                                                                |
|---------|----------------------------------------------------------------|
| • | U.S. holders whose functional currency is not the U.S. dollar; |

|         |                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------|
| • | partnerships or other entities classified as partnerships for U.S. federal income tax purposes; |

|         |                                                                |
|---------|----------------------------------------------------------------|
| • | persons who own ten percent (10%) or more of our voting stock; |

|         |                                                    |
|---------|----------------------------------------------------|
| • | persons subject to the alternative minimum tax; or |

|         |                           |
|---------|---------------------------|
| • | tax-exempt organizations. |

|         |                                             |
|---------|---------------------------------------------|
| • | a citizen or resident of the United States; |

|         |                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | a corporation or other entity taxed as a corporation created or organized in or under the laws of the United States, any state thereof or the District of Columbia; |

|         |                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------|
| • | an estate the income of which is subject to U.S. federal income taxation regardless of its source; or |

|         |             |
|---------|-------------|
| • | a trust if: |

|         |                                                                                                                                                                                               |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ◦ | a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons has the authority to control all substantial decisions of the trust or |

|         |                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------|
| ◦ | the trust was in existence on August 20, 1996 and properly elected to continue to be treated as a U.S. person. |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|         |                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------|
| • | Our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on February 19, 2013; |

|         |                                                                                                                                                                                                         |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013, and September 30, 2013 filed with the SEC on April 26, 2013, July 30, 2013, and October 29, 2013 respectively; |

|         |                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Our Current Reports on Form 8-K, filed with the SEC on January 29, February 20, March 5, May 2, June 11, July 25 (solely with respect to the information under Item 8.01), November 13 (solely with respect to the information under Items 1.01, 2.03, 3.02, and 9.01), and November 19, 2013; |

|         |                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | The information contained in our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 2, 2013 and incorporated into Part III of our Annual Report on Form 10-K for the year ended December 31, 2012; and |

|         |                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Our Registration Statement on Form 8-A, filed with the SEC on September 13, 2006, describing our common stock, and any amendment or report filed with the SEC for the purpose of updating the description. |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                                     |
|-----------------------------------------------------|
|                                                     |  |  |  |
| Securities and Exchange Commission Registration Fee | $ | 4,932 |  |
| Accounting Fees and Expenses                        | $ | 10,000 |  |
| Legal Fees and Expenses                             | $ | 27,500 |  |
| Total                                               | $ | 42,432 |  |

----

Table of Contents

----

Table of Contents

----

Table of Contents

| HEALTHSOUTH CORPORATION |
|-------------------------|
|                         |  |  |
|                    |   |   |
|                    |   |   |
| By:                     | /S/   John P. Whittington |
|                    | Name: | John P. Whittington, Esq. |
|                    | Title: | Executive Vice President, General Counseland Corporate Secretary |

----

Table of Contents

|                                                  |
|--------------------------------------------------|
|                                                  |  |  |
| Signature                                   | Capacity  | Date  |
|                                             |   |   |
| /s/ Jay GrinneyJay Grinney                       | President and Chief Executive Officer and Director | November 22, 2013 |
|                                             |   |   |
| /s/ Douglas E. ColtharpDouglas E. Coltharp       | Executive Vice President andChief Financial Officer | November 22, 2013 |
|                                             |   |   |
| /s/ Andrew L. PriceAndrew L. Price               | Chief Accounting Officer | November 22, 2013 |
|                                             |   |   |
| /s/ Jon F. Hanson Jon F. Hanson             | Chairman of the Board of Directors | November 22, 2013 |
|                                             |   |   |
| /s/ John W. Chidsey John W. Chidsey         | Director | November 22, 2013 |
|                                             |   |   |
| /s/ Donald L. Correll Donald L. Correll     | Director | November 22, 2013 |
|                                             |   |   |
| /s/ Yvonne M. Curl Yvonne M. Curl           | Director | November 22, 2013 |
| /s/ Charles M. Elson Charles M. Elson       | Director | November 22, 2013 |
|                                             |   |   |
| /s/ Joan E. Herman Joan E. Herman           | Director | November 22, 2013 |
|                                             |   |   |
| /s/ Leo I. Higdon, Jr.Leo I. Higdon, Jr.         | Director | November 22, 2013 |
|                                             |   |   |
| /s/ Leslye G. KatzLeslye G. Katz                 | Director | November 22, 2013 |
|                                             |   |   |
| /s/ John E. Maupin, Jr. John E. Maupin, Jr. | Director | November 22, 2013 |
|                                             |   |   |
| /s/ L. Edward Shaw, Jr. L. Edward Shaw, Jr. | Director | November 22, 2013 |

----

Table of Contents

|       |
|-------|
|       |  |
| No.   | Description |
| 1.1   | Form of Underwriting Agreement.** |
| 3.1   | Restated Certificate of Incorporation of HealthSouth Corporation, as filed in the Office of the Secretary of State of the State of Delaware on May 21, 1998 (incorporated by reference to HealthSouth's Annual Report on Form 10-K filed with the SEC on June 27, 2005). |
| 3.2   | Certificate of Amendment to the Restated Certificate of Incorporation of HealthSouth Corporation, as filed in the Office of the Secretary of State of the State of Delaware on October 25, 2006 (incorporated by reference to Exhibit 3.1 to HealthSouth's Current Report on Form 8-K filed on October 31, 2006). |
| 3.3   | Amended and Restated Bylaws of HealthSouth Corporation, effective as of October 30, 2009, (incorporated by reference to Exhibit 3.3 to HealthSouth's Quarterly Report on Form 10-Q filed on November 4, 2009). |
| 3.4   | Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March 7, 2006 (incorporated by reference to Exhibit 3.1 to HealthSouth's Current Report on Form 8-K filed on March 9, 2006). |
| 4.1.1 | Warrant Agreement, dated as of January 16, 2004, between HealthSouth Corporation and Wells Fargo Bank Northwest, N.A., as warrant agent (incorporated by reference to Exhibit 10.2 to HealthSouth's Current Report on Form 8-K filed on January 20, 2004). |
| 4.1.2 | Registration Rights Agreement, dated as of January 16, 2004, among HealthSouth Corporation and the entities listed on the signature pages thereto as holders of Warrants and transfer restricted securities (incorporated by reference to Exhibit 10.3 to HealthSouth's Current Report on Form 8-K filed on January 20, 2004). |
| 4.2   | Warrant Agreement, dated as of September 30, 2009, among HealthSouth Corporation and Computershare Inc. and Computershare Trust Company, N.A., jointly and severally as warrant agent (incorporated by reference to Exhibit 4.1 to HealthSouth's Registration Statement on Form 8-A filed on October 1, 2009). |
| 4.3.1 | Indenture, dated as of December 1, 2009, between HealthSouth Corporation and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth's 8.125% Senior Notes due 2020, 7.250% Senior Notes due 2018, and 7.750% Senior Notes due 2022 (incorporated by reference to Exhibit 4.7.1 to HealthSouth's Annual Report on Form 10-K filed on February 23, 2010.) |
| 4.3.2 | First Supplemental Indenture, dated December 1, 2009, among HealthSouth Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth's 8.125% Senior Notes due 2020 (incorporated by reference to Exhibit 4.7.2 to HealthSouth's Annual Report on Form 10-K filed on              February 23, 2010). |
| 4.3.3 | Second Supplemental Indenture, dated October 7, 2010, among HealthSouth Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth's 7.250% Senior Notes due 2018 (incorporated by reference to Exhibit 4.2 to HealthSouth's Current Report on Form 8-K filed on             October 12, 2010). |
| 4.3.4 | Third Supplemental Indenture, dated October 7, 2010, among HealthSouth Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth's 7.750% Senior Notes due 2022 (incorporated by reference to Exhibit 4.3 to HealthSouth's Current Report on Form 8-K filed on           October 12, 2010). |
| 4.3.5 | Fourth Supplemental Indenture, dated September 11, 2012, among HealthSouth Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth's 5.75% Senior Notes due 2024 (incorporated by reference to Exhibit 4.2 to HealthSouth's Current Report on Form 8-K filed on          September 11, 2012). |
| 4.3.6 | Indenture, dated November 18, 2013, between HealthSouth Corporation and Wells Fargo, National Association, as trustee, paying agent, conversion agent, and registrar, relating to HealthSouth's 2.00% Convertible Senior Subordinated Notes due 2043 (incorporated by reference to Exhibit 4.1 to HealthSouth's Current Report on Form 8-K filed November 19, 2013). |
| 5.1   | Opinion of Stephen D. Leasure, Esq., as to the validity of the securities.* |
| 23.1  | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.* |
| 23.2  | Consent of Stephen D. Leasure, Esq. (included in Exhibit 5.1).* |
| 24    | Power of Attorney (included as part of signature page). |

----

Table of Contents